Chronic myeloid leukemia, BCR/ABL transcript, response to α-interferon and survival

Leukemia

Volumn 9, Issue 10, 1995, Pages 1648-1652

  Baccarani, M ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

BCR ABL; Interferon; Leukemia (chronic myeloid); Philadelphia chromosome; Prognosis

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; HYDROXYUREA; MELPHALAN; MESSENGER RNA; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER GENETICS; CANCER SURVIVAL; CHROMOSOME 22; CHROMOSOME BREAKAGE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; FEMALE; GENE FUSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0028812716     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Dreazen O, Canaani E, Gale RP. Molecular biology of chronic myelogenous leukemia. Semin Hematol 1988; 25: 35-49.
2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319: 990-998.
3. bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
4. Heisterkamp N et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251-253.
5. Eisenberg A et al. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 1988; 2: 642-647.
6. Shtalrid M et al. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 1988; 72: 485-490.
7. Mills KI, MacKenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 1988; 72: 1237-1241.
8. Przepiorka D. Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis. Cancer Genet Cytogenet 1988; 36: 123-130.
9. Grossman A et al. Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. Am J Hum Genet 1989; 45: 729-738.
10. Mills KI et al. Further evidence that the site of the breakpoint in the major breakpoint cluster region (M-bcr) may be a prognostic indicator. Leukemia 1989; 12: 837-840.
11. Ogawa H et al. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients. Leukemia 1989; 3: 492-496.
12. Morris SW et al. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990; 75: 2035-2041.
13. Jaubert J et al. The position of the M-bcr breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia. Br J Haematol 1990; 74: 30-35.
14. Tien HF et al. Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease. Br J Haematol 1990; 75: 469-475.
15. Tefferi A et al. The location of the Philadelphia chromosome breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia 1990; 4: 839-842.
16. Opalka B et al. Breakpoint localization within the M-bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy. Leukemia 1991; 5: 452-456.
17. Zaccaria A et al. M-bcr breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 1992; 77: 16-20.
18. Zaccaria A et al. The type of bcr/abl junction does not predict the survival of patients with Ph1-positive chronic myeloid leukemia. Br J Haematol 1993; 84: 265-268.
19. Zaccaria A, Martinelli G, Buzzi M, Farabegoli P. Will molecular biology contribute to refine prognosis and to select treatment? Leuk Lymphoma 1993; 11 (suppl 1): 81-89.
20. Morgan GJ et al. The role of alternative splicing patterns of bcr/abl transcript in the generation of the blast crisis of chronic myeloid leukemia. Br J Haematol 1990; 76: 33-38.
21. Inoue T et al. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α-interferon in chronic myelogenous leukemia. Leukemia 1992; 6: 984-951.
22. Italian Cooperative Study Group (ICSG) on Chronic Myeloid Leukemia. Karyotypic conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Leuk Lymphoma 1993; 11 (suppl. 1): 277-280.
23. Italian Cooperative Study Group on Chronic Myeloid Leukemia. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia: clinical and cytogenetic results at 2 years in 322 patients. Haematologica 1992; 77: 204-214.
24. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
25. Saglio G et al. New type of BCR/ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990; 76: 1819-1824.
26. Guerrasio A et al. Minimal residual disease status in transplanted chronic myeloid leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. Leukemia 1992; 6: 507-512.
27. Shtivelman E et al. Alternative splicing of NAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1988; 47: 277-284.
28. Martinelli G et al. Molecular genetic analysis of bcr breakpoint in Philadelphia chromosome rearrangements and correlation with prognosis and age of chronic myelogenous leukaemia patients. In: Bartsocos CS, Loukopoulos D, (eds). Genetics of Hematological Disorders Hemosphere Publishing: Washington DC, 1992, pp 185-193.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 357-481.
30. Peto R et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patients. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
31. Sokal JE et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
32. Birnie GD, Mills KI, Benn P. Does the site of the breakpoint on chromosome 22 influence the duration of the chronic phase in chronic myeloid leukemia? Leukemia 1989; 3: 545-547.
33. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991; 78: 1155-1161.
34. Talpaz M et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532-538.